# Cognex (CGNX) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-12  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/CGNX/thesis · /stocks/CGNX/memo

## Financial Snapshot

---
source: coverage-next-full
step: 04
title: Financial Quality & Adversarial Research Sweep
ticker: CGNX
company: Cognex Corporation
created: 2026-06-11
---

### Step 04 — Financial Quality & Adversarial Research Sweep: Cognex Corporation (CGNX)

---

#### 1. Financial Quality Overview

Cognex Corporation's financial statements are among the cleaner examples in the industrial technology sector [S1]. The company files on a calendar-year basis with the SEC as a domestic filer (10-K, 10-Q, 8-K). Annual audits are conducted by **PricewaterhouseCoopers LLP**, a Big Four auditor. PwC has issued unqualified (clean) audit opinions consistently; there are no material weaknesses or significant deficiencies disclosed in any recent filing period.

**Revenue recognition** follows ASC 606 under a relatively simple model: the vast majority of Cognex's revenues are recognized at a **single point in time upon product delivery and customer acceptance**. There are no significant multi-element arrangements, no percentage-of-completion accounting, and no material contract assets or liabilities that could obscure revenue timing. Software licenses embedded in hardware (VisionPro, In-Sight firmware) are bundled with the hardware under a combined performance obligation model — this is clean and consistent with industry practice.

The company's reporting structure — single reportable segment — reduces complexity but limits transparency. Investors and analysts are reliant on qualitative commentary and disaggregated geographic revenue tables (disclosed in the 10-K) rather than formal segment P&Ls. This is a limitation for modeling but not an accounting quality concern [S1].

---

#### 2. Income Statement Quality Adjustments

Cognex reports both GAAP and non-GAAP (adjusted) results. The primary non-GAAP adjustments are: (a) stock-based compensation, (b) amortization of acquired intangible assets, and (c) discrete tax items.

##### Stock-Based Compensation (SBC)
SBC was **$48.5M in FY2025**, representing **4.9% of revenue** [S2]. This is a meaningful and recurring cost. GAAP diluted EPS of approximately $0.68 per share for FY2025 compares to adjusted (non-GAAP) EPS of approximately $1.02 per share — a 50% premium for adjusted metrics driven primarily by SBC exclusion. Investors relying exclusively on adjusted EPS risk overestimating the true cash earnings available to common shareholders, since SBC is a real dilution event. Cognex's option and RSU grants are concentrated among the technical and commercial workforce (not unusual for a software-IP-intensive hardware company), but the absolute dollar amount has been stable-to-growing even as headcount has been managed tightly.

SBC as a percentage of revenue has declined modestly — from 6.5% in FY2023 to 4.9% in FY2025 — as the revenue recovery has grown the denominator faster than grant sizes have increased. Nevertheless, any investor using adjusted EPS for valuation purposes should capitalize the SBC run-rate as an ongoing cost of the equity [S2].

##### Amortization of Acquired Intangibles
The Moritex acquisition (Q4 2023, ~$135M purchase price) added approximately $10–12M of annual amortization from acquired developed technology and customer relationships. This is included in D&A and excluded from adjusted EBITDA. The amortization is a real economic cost to the extent it reflects IP that must be maintained or replaced, but in Cognex's case the underlying Moritex optical IP is being actively used in products, making the GAAP treatment reasonable.

##### Interest and Investment Income
Cognex earns substantial investment income on its $600–700M portfolio of AFS (available-for-sale) securities and money market instruments. In FY2025, net investment income was approximately $25–35M, and in Q1 2026 this line contributed meaningfully to reported pre-tax income. Because this income is non-operational, analysts constructing an operating business valuation should strip it out when calculating enterprise value metrics. Failure to do so will overstate operating margins if investment income is included in net margin calculations. GAAP net income includes this income; EBITDA from operations does not [S2].

##### Adjusted Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue ($M) | $837.5 | $914.5 | $994.4 |
| Gross Profit ($M) | $601.5 | $625.1 | $665.0 |
| Gross Margin | 71.8% | 68.4% | 66.9% |
| GAAP Operating Income ($M) | $130.6 | $115.2 | $162.0 |
| GAAP Operating Margin | 15.6% | 12.6% | 16.3% |
| Adj. EBITDA ($M, est.) | ~$152M | ~$148M | ~$193M |
| Adj. EBITDA Margin | ~18.2% | ~16.2% | ~19.4% |
| GAAP Diluted EPS | ~$0.56 | ~$0.61 | ~$0.68 |
| Adj. Diluted EPS | ~$0.76 | ~$0.82 | ~$1.02 |

---

#### 3. Cash Flow Quality

Cognex's free cash flow generation is exceptional in structural terms, though it is highly cyclical in absolute magnitude [S3].

**FCF conversion (FCF / GAAP Net Income)**:
- FY2023: 79% ($89.8M FCF / $113M net income) — depressed by working capital build
- FY2024: 126% ($134M / $106M) — working capital release begins
- FY2025: 207% ($236.8M / $114M) — strong working capital release + low CapEx

The >100% conversion in FY2024–2025 reflects three structural factors:

1. **Non-cash charges**: D&A of ~$31M annually is added back; SBC of ~$49M is added back in the cash flow statement but represents economic dilution, not cash out the door. Together these represent ~$80M of non-cash charges that inflate operating cash flow relative to net income.

2. **Minimal CapEx**: FY2025 CapEx was only $8.7M (0.9% of revenue). Cognex's manufacturing is largely outsourced; the company does not own fab capacity. The primary capital-consuming activity is R&D (expensed), not physical plant. This is a critical quality signal — Cognex's earnings do not require reinvestment capital to maintain, making FCF a more accurate representation of economic earnings than net income.

3. **Working capital dynamics**: Cognex builds inventory in anticipation of demand cycles (a risk discussed in Section 6). In recovery phases (FY2024–2025), inventory drawdowns release cash. In boom phases (FY2021), working capital consumed cash. The FY2023 low FCF reflected inventory build ahead of a recovery that came more slowly than anticipated. This pattern is important — it means FCF is a leading indicator of demand expectations (high FCF = management drawing down inventory, implying caution; low FCF = management building inventory, implying anticipated demand ramp) [S3].

---

#### 4. Balance Sheet Quality

Cognex maintains a **fortress balance sheet** with zero financial (interest-bearing) debt, a large liquid investment portfolio, and moderate goodwill/intangibles from a single meaningful acquisition [S4].

**Liquidity position (FY2025 year-end)**:
- Cash and short-term investments: ~$337M
- Available-for-sale securities (long-term portion): ~$379M
- **Total liquid assets: ~$716M**
- Financial debt: $0
- **Net cash position: ~$640M (enterprise value adjusted)**

The AFS securities portfolio is held in high-quality instruments (government bonds, agency securities, investment-grade corporate bonds). There is minimal credit risk, and the portfolio generates the investment income discussed in Section 2.

**Goodwill and intangibles**: Total goodwill of approximately $380M (primarily from Moritex and earlier acquisitions including Matrox Imaging in 2022). Intangible assets of approximately $180–200M (acquired developed technology, customer relationships). These numbers are not alarming relative to equity of $1.492B (goodwill/equity ~25%). The company performs annual impairment testing; no goodwill impairment has been recorded [S4].

**Working capital health**: Current ratio approximately 3.8x; quick ratio approximately 3.0x. Accounts receivable days are approximately 50–60 days, consistent with the industrial technology sector norm. Inventory turns are somewhat lower than software-rich peers, reflecting the hardware component of the business.

There is no risk of financial distress, covenant breach, or liquidity constraint at current leverage levels. The balance sheet provides substantial M&A optionality — the company could add $500M–$1B of acquisition financing without approaching concerning leverage ratios given its FCF profile [S4].

---

#### 5. Return Metrics

**ROIC (FY2025 estimate)**: Net operating profit after tax (NOPAT) of approximately $163M operating income × (1 − 18% tax rate) = ~$134M. Invested capital: equity of $1,492M minus net cash of $640M = approximately $852M of operating invested capital (adding back goodwill and intangibles for a more conservative measure gives ~$1.85B). Using the operating capital base of ~$852M, ROIC is approximately **15.7%**. Using the more conservative invested capital including goodwill (~$1.85B), ROIC is approximately **7.2%** [S5].

The gap between the two ROIC measures reflects the debate about whether Moritex goodwill and legacy acquisition intangibles represent genuine capital deployed at risk. Stripping goodwill gives a cleaner picture of the organic business's returns on tangible capital, which are very high — consistent with a software-IP moat business.

**Historical ROIC context**:
- FY2021 peak: ~19–22% (NOPAT ~$257M / ~$1.2B invested capital)
- FY2023 trough: ~5–6% (NOPAT ~$107M / ~$1.8B invested capital including Moritex goodwill acquired at cycle trough)
- FY2025: ~7–9% on full invested capital; ~15–17% on operating capital (ex-cash, ex-goodwill)

**WACC estimate**: 7–8%. Cognex's equity beta (5-year monthly) is approximately 1.53 — elevated for a quality compounder because the stock is highly cyclical and levered to industrial capex cycles. Using a 5.0% equity risk premium and 4.5% risk-free rate: cost of equity = 4.5% + 1.53 × 5.0% = ~12.2%. With no debt, WACC ≈ cost of equity ≈ 12%. The spread between current ROIC (7–9% on full IC) and WACC (12%) is negative at trough, but at cycle-peak ROIC of 19–22%, the spread is strongly positive. This means Cognex creates economic value through the cycle, but only materially so near or above the revenue peak [S5].

---

#### 6. Accounting Red Flags — Adversarial Research Sweep

This section systematically examines potential accounting risks identified through review of SEC filings, proxy statements, and adversarial research. **Overall conclusion: No material accounting red flags identified.**

##### Short-Seller Reports
No meaningful short-seller research campaigns against Cognex have been identified in the public record. Cognex is a long-tenured S&P 500 company (founded 1981, public since 1993) with continuous auditor coverage by PwC. The company's business model — selling physical hardware with embedded software — does not lend itself to the revenue recognition manipulations that attract short-seller attention (e.g., SaaS companies with aggressive deferred revenue treatment, or companies recognizing channel sales on consignment) [S6].

##### SEC Enforcement / Comment Letters
A review of SEC EDGAR correspondence files shows no material enforcement actions or unresolved comment letter issues with revenue recognition, internal controls, or disclosure compliance for Cognex. The company has not disclosed any material weaknesses in internal controls over financial reporting (ICFR) in its Section 404 assessments [S6].

##### Related-Party Transactions
Cognex was founded by Robert Shillman, who served as a dominant figure through the early decades. Founder-era related-party arrangements (including IP licensing from entities controlled by insiders) have been largely resolved as the company professionalized. The current proxy statement discloses standard related-party policies and no material ongoing related-party transactions. The board's Audit Committee oversight appears appropriate for a company of this size [S6].

##### Revenue Recognition Complexity
ASC 606 application at Cognex is low-complexity. The company does not have significant variable consideration, no financing components, and no warranty obligations that are sufficiently separate to constitute a distinct performance obligation under GAAP. The deferred revenue balance (for multi-year service contracts) is small and declining as a percentage of revenue — no red flags on revenue pull-forward [S6].

##### Inventory Quality and Channel Inventory Dynamics
Inventory management at Cognex warrants scrutiny given the cyclical revenue pattern. Days Inventory Outstanding (DIO) in FY2023 was elevated — the company entered 2023 with inventory built for an anticipated demand recovery that materialized more slowly than expected. This is not a fraud indicator but it is an operational concern, as elevated channel inventory can delay recognition of a genuine demand recovery.

The more material risk is **distributor inventory**: Cognex sells through system integrators and VARs who carry their own inventory of Cognex products. When Cognex recognizes revenue upon shipment to the integrator (not to the end customer), there is a structural risk that integrators may slow orders if they have excessive stock — creating "double-inventory" risk at the channel level. The FY2023 revenue decline was partly attributed to channel destocking. This is now resolved, but it is a recurring cyclical risk [S6].

##### Non-GAAP Adjustments: SBC Exclusion
The most legitimate accounting concern for Cognex is the **ongoing exclusion of SBC from non-GAAP metrics**. At $48.5M annually (FY2025), SBC represents dilution of approximately 4.9% of revenue. Sell-side consensus and most public valuation frameworks use adjusted (non-GAAP) EPS, which excludes SBC. This creates systematic overstatement of earnings quality if adjusted EPS is used without an SBC haircut. Cognex does not guide to GAAP EPS — the company's guidance uses non-GAAP operating income and non-GAAP EPS, which institutional investors are well aware of but which retail investors may misread as the true economic earnings.

**The appropriate treatment**: Use GAAP net income as the base, or add back only the non-cash D&A amortization (not SBC) when constructing normalized earnings. FCF is the most reliable metric as it reflects actual cash generation after SBC-induced dilution [S6].

##### Moritex Goodwill Impairment Risk
The Moritex acquisition was completed in Q4 2023 at approximately $135M — a machine vision accessories business based in Japan, primarily serving Asian customers. Goodwill allocated to Moritex is embedded in the company's single reporting unit, making it difficult to isolate the Moritex-specific impairment risk. If machine vision accessories demand in Asia remains depressed for an extended period, there is a theoretical goodwill impairment risk. However, given that Moritex's carrying value is modest relative to overall enterprise value (~$135M versus ~$5B EV), even a full impairment would be manageable [S6].

---

#### 7. Capital Structure & Leverage

Cognex's capital structure is a textbook example of a zero-leverage compounding business [S7]:

**Debt**: Zero long-term financial debt. Operating lease obligations of approximately $65M (primarily office and lab space leases globally). No convertible notes, no revolving credit facility drawn.

**Net cash evolution (FY2023–Q1 2026)**:
- FY2023 year-end: ~$550M net cash (pre-Moritex full integration)
- FY2024 year-end: ~$590M net cash
- FY2025 year-end: ~$640M net cash
- Q1 2026 (estimated): ~$620M (after Q1 shareholder returns)

**Cash deployment FY2024–2025**:
- Share buybacks: $67M (FY2024), $151M (FY2025) — the accelerated FY2025 buyback at cycle trough prices demonstrates confident capital allocation
- Dividends: $52M (FY2024), $55M (FY2025) — modest yield (~0.6%) but demonstrates commitment to returning cash
- M&A: Moritex was completed in Q4 2023; no follow-on acquisitions have been disclosed

**M&A capacity**: With $640M net cash, zero debt, and FCF generation of $200–250M annually, Cognex could fund an acquisition of $500M–$1B without any equity issuance, or up to $1.5–2B with modest leverage (2–3x EBITDA). The company has historically been acquisitive at the edges (adjacent vision technologies) rather than transformative, and there is no indication that strategy has changed [S7].

---

#### 8. Financial Quality Rating & Key Metrics Table

| Metric | FY2023 | FY2024 | FY2025 | Q1 2026 TTM |
|---|---|---|---|---|
| Revenue ($M) | $837.5 | $914.5 | $994.4 | ~$1,047 |
| Gross Margin | 71.8% | 68.4% | 66.9% | ~68.0% |
| Operating Margin | 15.6% | 12.6% | 16.3% | ~18.8% |
| Adj. EBITDA Margin | ~18.2% | ~16.2% | ~19.4% | ~21.6% |
| FCF ($M) | $89.8 | $134.0 | $236.8 | ~$241 |
| FCF Margin | 10.7% | 14.7% | 23.8% | ~23.0% |
| FCF Conversion (FCF/NI) | 79% | 126% | 207% | ~169% |
| SBC / Revenue | 6.5% | 5.7% | 4.9% | ~4.8% |
| ROIC (full IC, est.) | ~5.5% | ~5.8% | ~8.8% | ~11% est. |
| Net Cash ($B) | ~$0.55 | ~$0.59 | ~$0.64 | ~$0.62 |
| D/EBITDA | 0.0x | 0.0x | 0.0x | 0.0x |
| Current Ratio | ~3.5x | ~3.7x | ~3.8x | ~3.9x |

**Overall Financial Quality Rating: HIGH** [S8]

Cognex's financial statements are transparent, internally consistent, and supported by a clean audit history. Cash generation is genuine and unencumbered by working capital traps or hidden leverage. The balance sheet is a source of strength — not just safety — providing M&A optionality and buyback capacity through cycles. The single legitimate concern is the magnitude of non-GAAP SBC exclusion, which investors should consciously haircut when building valuation models. There are no material accounting red flags, no related-party concerns, and no revenue recognition risks that would reduce confidence in reported financials.

The compression of ROIC from ~20% (FY2021) to ~8–9% (FY2025) on a full invested capital basis is a real fundamental concern — not an accounting concern — and reflects the combination of cyclically depressed margins and the Moritex acquisition adding to the capital base at a trough. As margins recover toward the FY2021 baseline (a plausible 3–5 year scenario given AI vision tailwinds), ROIC on full invested capital should recover toward 14–18%, well above a reasonable WACC and supportive of value creation through the next cycle [S8].

---

*Sources: [S1] 10-K FY2024/FY2025 auditor opinion; SEC filings EDGAR search. [S2] XBRL financial data; StockAnalysis.com adjusted EPS; GAAP/non-GAAP reconciliation tables in 10-K. [S3] StockAnalysis.com cash flow statement; XBRL cash flow data. [S4] XBRL balance sheet data; Moritex acquisition 8-K; goodwill footnote in 10-K. [S5] Derived ROIC from XBRL operating income and balance sheet; beta from market data. [S6] Proxy filing (DEF 14A); SEC EDGAR comment letter correspondence; adversarial research; channel inventory discussion in 10-K MD&A. [S7] XBRL cash flow statement (buyback + dividend line items); balance sheet debt footnote. [S8] Composite derived metrics from above sources.*

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/CGNX/fundamental

## Navigation

- Overview: /stocks/CGNX
- Financials (this page): /stocks/CGNX/financials
- Thesis: /stocks/CGNX/thesis
- Investment Memo: /stocks/CGNX/memo
- Coverage universe: /stocks